David Alexander Learmonth

This inventor holds 42 USPTO granted patents and 19 published patent applications, plus 20 CIPO patents and 26 EPO patents, primarily in COMT Inhibitors. Top assignees: Bial-Portela Ca & S.a., Portela, C.a., S.a., Stemmatters, Biotecnologia E Medicina Regenerativa. Active years: 1999-2024.

USPTO Granted Patents = 42 (Patent Applications = 19)

% Patents Active = 69.0

CIPO Patents = 20

EPO Patents = 26 (Patent Applications = 24)

Average Co-Inventor Count = 2.7

ph-index = 8

Forward Citations = 171(Granted Patents)

Location History:

Maia, PT (1999 - 2007)
São Mamede do Coronado, PT (2016)
Valongo, PT (2010 - 2017)
Valonga, PT (2017)
S. Mamede do Coronado, PT (2013 - 2018)
Alfena, PT (2006 - 2022)

Company Filing History:

29 out of 52

Bial-Portela Ca & S.a.

Stemmatters, Biotecnologia E Medicina Regenerativa

patent

4. 1 out of 2

Stemmatters, Biotecnologia E Medicina Regenerativa, S.a.

patents

5. 1 out of 834,411

Other

patents

Years Active: 1999-2024

Loading Chart...

Areas of Expertise:

COMT Inhibitors

Nitrocatechol Derivatives

Pharmaceutical Compounds

Asymmetric Catalytic Reduction

Hydrogels

Dopamine-Beta-Hydroxylase

Chiral Inversion

Synthetic Intermediates

Catalytic Hydrogenation

Gellan Gum

1,3-Dihydroimidazole

Dosage Regimen

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12129247 - Administration regime for nitrocatechols (2024-10-29),

2. 11352447 - Gellan gum hydrogels, preparation, methods and uses thereof (2022-06-07),

3. 10927193 - Gellan gum-based hydrogels, methods and uses thereof (2021-02-23),

4. 10336740 - Nitrocatechol derivatives as COMT inhibitors (2019-07-02),

5. 10065944 - Administration regime for nitrocatechols (2018-09-04),

6. 10059696 - Process for preparing 1,3-dihydroimidazole-2-thione derivatives (2018-08-28),

7. 9845316 - Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol (2017-12-19),

8. 9745290 - Dosage regimen for COMT inhibitors (2017-08-29),

9. 9643929 - Asymmetric catalytic reduction of oxcarbazepine (2017-05-09),

10. 9630955 - Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor (2017-04-25),

11. 9630951 - 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase (2017-04-25),

12. 9550759 - Nitrocatechol derivatives as COMT inhibitors (2017-01-24),

13. 9458111 - Process for the synthesis of substituted urea compounds (2016-10-04),

14. 9446012 - Pharmaceutical compounds (2016-09-20),

15. 9353082 - Pharmaceutical compounds (2016-05-31),

Title: David Alexander Learmonth: Pioneering Innovations in Hydrogels and Regenerative Medicine

Introduction:

David Alexander Learmonth is a visionary inventor based in Alfena, Portugal, with a remarkable passion for innovation. With a notable reputation for his relentless pursuit of excellence, Learmonth's contributions to technology continue to inspire and shape the future of innovation worldwide.

Latest Patents:

Learmonth holds an impressive 41 patents, with his latest inventions focusing on gellan gum hydrogels. These innovative hydrogels offer versatile applications in in vitro cell culture, tissue engineering, and regenerative medicine. By incorporating live cells and biomolecules, Learmonth's gellan gum-based hydrogels demonstrate tunable physicochemical and biological properties, surpassing existing hydrogel systems in solubility, crosslinking versatility, and tissue adhesiveness.

Career Highlights:

Throughout his illustrious career, Learmonth has made significant strides in the field of biotechnology. He has worked with esteemed companies such as Bial-Portela & Ca S.A., where his innovative research has paved the way for advancements in regenerative medicine. Learmonth's expertise in gellan gum-based hydrogels has revolutionized the landscape of bone, cartilage, and soft tissue engineering.

Collaborations:

Collaborating with talented individuals is essential to Learmonth's success. Notable coworkers such as Alexander Beliaev and Laszlo Erno Kiss have been instrumental in bringing his groundbreaking inventions to fruition. Together, they have synergized their expertise to push the boundaries of innovation in biomedicine.

Conclusion:

In conclusion, David Alexander Learmonth's dedication to innovation and his groundbreaking work in gellan gum hydrogels exemplify his visionary outlook on the future of regenerative medicine. His relentless pursuit of excellence continues to inspire and shape the landscape of technology, setting new benchmarks for inventors worldwide.